Short Interest in Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) Increases By 67.1%

Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) saw a significant growth in short interest during the month of November. As of November 15th, there was short interest totalling 66,000 shares, a growth of 67.1% from the October 31st total of 39,500 shares. Approximately 9.7% of the company’s stock are short sold. Based on an average daily trading volume, of 58,000 shares, the short-interest ratio is presently 1.1 days.

Cadrenal Therapeutics Trading Up 7.3 %

NASDAQ CVKD opened at $15.19 on Friday. Cadrenal Therapeutics has a 1 year low of $5.40 and a 1 year high of $32.55. The business’s fifty day moving average price is $14.66. The company has a market cap of $25.20 million, a P/E ratio of -2.27 and a beta of 1.52.

Analyst Upgrades and Downgrades

Separately, HC Wainwright increased their price objective on Cadrenal Therapeutics from $3.00 to $32.00 and gave the company a “buy” rating in a report on Monday, November 11th.

Cadrenal Therapeutics Company Profile

Cadrenal Therapeutics, Inc operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome.